Alzheimer’s Disease Treatment Special Notice – January 6, 2023:

The U.S. Food and Drug Administration (FDA) approved a new drug, lecanemab-irmb injection (Leqembi™), for treatment of persons with early Alzheimer’s disease. This stage includes persons with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Current FDA approval of this drug is based on the “accelerated approval” pathway. Currently, Medicare will NOT provide payment coverage for this drug other than in clinical trials. Once “traditional” FDA approval is obtained, which may occur later in 2023, broader coverage should be available. We will update this message as more information is released.